Fact Check: Can This 'Supercharged' Drug Really End Antibiotic Resistance
A breakthrough in antibiotic resistance was reported last week. Scientists had re-engineered the drug vancomycin—used against extremely resistant infections including MRSA—to make it stronger and stop bugs becoming immune to it. Vancomycin has been prescribed for 60 years and is a highly effective antibiotic—yet in some countries bacteria are developing resistance.
Professor Dale Boger, of the Scripps Research Institute, California, had previously managed to make two tweaks to the drug in the lab to make it more potent. Last week, his team announced a final tweak, which when combined with the previous two would make it 1,000 times stronger than it was in its original form, and bacteria would no longer be able to resist it.
In a press release announcing the breakthrough, Boger called vancomycin "magical" for its proven strength against infections, and said his team's modifications had given the drug "superpowers." The release described the breakthrough as "an advance that could eliminate the threat of antibiotic-resistant infections for years to come."
Reporting on the story, British media outlets used similar language. A Daily Express headline announced the new vancomycin "could spell end of antibiotic resistant infections." The Sun said scientists believed the breakthrough could "hold off the threat of antibiotic resistance."
So does the development of this new drug really mark the end of superbugs? Professor Peter Wilson, a consultant microbiologist at University College London Hospital, is doubtful. The new vancomycin is only effective against one family of bacteria called "gram-positives," he pointed out, which only account for some of the infections seen in hospitals. Most of these infections are not resistant to standard antibiotics and so the "super" vancomycin would have very little effect, he said.
What is antibiotic resistance and why is it so dangerous?
Both vancomycin-resistant enterococci (VRE) and VRSA feature on the World Health Organization's list of bugs posing the greatest risk to mankind because there are so few drugs that can work against them. If scientists were able to make the new vancomycin into a drug it would be "fantastic" and doctors would welcome it, said Dr. Tim Jinks, head of drug resistant infections at the Wellcome Trust. Yet in practical terms the drug could only be used against a handful of infections.
Gram-positive infections include enterococci—bugs commonly found in the gut which can sometimes cause an infection, especially in patients already unwell with other illnesses. In the study, the beefed-up vancomycin was tested and found to be effective against normal enterococci and vancomycin-resistant forms of the bug. Other gram-positive infections treated with vancomycin include Staphylococcus aureus and its resistant types: methicillin resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Staphylococcus aureus (VRSA). VRSA is exceedingly rare in the UK.
Both Wilson and Jinks agreed that another family of bacteria—known as "gram-negatives"—pose a greater threat in the UK. Gram-negative infections—such as E.coli and Klebsiella—are a major cause of blood poisoning and are more likely to become resistant to antibiotics. E.coli is the most common cause of bloodstream infections in the UK. There were 38,000 bloodstream infections from E.coli in 2016 in England, compared to 1,099 in 2015/16 from MRSA. The new vancomycin would not work against a number of serious and life-threatening infections, both experts agreed.
It is also important to note the changes made to vancomycin were carried out in the lab. There were 30 steps involved to achieve the modified version. In order for the new drug to become available in hospitals and nursing homes, scientists would have to find a way to engineer—or synthesize it—with fewer steps and en masse.
Then, it would have to go through trials in order to become licensed and be tested for efficacy and safety on humans. That could take at least five years, said Jinks. The results are encouraging but there remains a desperate need for continued research and innovation to create new antibiotics, he said.
The Bureau asked Boger for comment but he declined to respond.
Monsanto, the maker of the glyphosate-based herbicide Roundup, filed a motion June 16 in U.S. District Court, Northern District of California to reconsider the chemical's addition to California's Proposition 65 list of agents known to cause cancer.
The agrochemical giant made this move based on a June 14 Reuters investigation of Dr. Aaron Blair, a lead researcher on the World Health Organization's International Agency for Research on Cancer (IARC) committee, that classified glyphosate as a "2A probable human carcinogen" in March 2015.
By Avery Friedman
Algae is often considered a nuisance, but for Sweden, the rapidly growing sea plant is now an asset.
As the Scandinavian country works to cut all of its greenhouse gas emissions by 2045, it's using algae to sop up the carbon emissions from cement.
By Itai Vardi
A recent intensification in protests against Williams Partners' planned Atlantic Sunrise pipeline in Pennsylvania prompted a state senator to propose legislation aimed at limiting demonstrations.
Last month, Pennsylvania Sen. Scott Martin (R-Norman) announced his intention to introduce legislation that would pass the costs of law enforcement responding to protests onto the demonstrators. Martin also helped introduce a different bill that would criminalize protests at natural gas facilities.
The so-called "first and last mile" problem is one of the biggest hurdles with public transportation. How do you encourage more people to take Earth-friendlier commutes when their homes are miles away from the train or bus station?
One solution, as this Estonian electric scooter company proposes, is to simply take your commute with you—literally. Tallinn-based Stigo has developed a compact e-scooter that folds to the size of a rolling suitcase in about two seconds.
[Editor's note: I'm still in shock after hearing the news that Lucia Grenna passed away in her sleep last week. When we first met in April of 2014 at a Copenhagen hotel, I was immediately taken by here powerful presence. We spent the next couple days participating in a Sustainia climate change event where Lucia presented her audacious plans to connect people to the climate issue. I had the chance to partner with Lucia on several other projects throughout the years and work with her incredible Connect4Climate team. I was always in awe of her ability to "make the impossible possible." Her spirit will live on forever. — Stefanie Spear]
It is with a heavy heart that Connect4Climate announces the passing of its founder and leading light, Lucia Grenna. Lucia passed peacefully in her sleep on June 15, well before her time. We remember her for her leadership and extraordinary ability to motivate people to take on some of the greatest challenges of our time, not least climate change.
By Stacy Malkan
Neil deGrasse Tyson has inspired millions of people to care about science and imagine themselves as participants in the scientific process. What a hopeful sign it is to see young girls wearing t-shirts emblazoned with the words, "Forget princess, I want to be an astrophysicist."
As Trevor Noah noted during The Daily Show episode last night (starts at 2:25), the real reason Trump has these rallies is to "get back in front of his loyal crowds and feed of their energy." Noah believes that "Trump supporters are so on board with their dude he can say anything and they'll come along for the ride."